The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
Open accessAbstract
Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter retrospective study describes the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% CI, 6.8-12.8). The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95% CI, 2.4-10.7), respectively. Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization (D-dimer >2500 ng/mL, adjusted odds ratio [OR] for thrombosis, 6.79 [95% CI, 2.39-19.30]; adjusted OR for bleeding, 3.56 [95% CI, 1.01-12.66]), critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450 × 109/L (adjusted OR, 3.56 [95% CI, 1.27-9.97]), C-reactive protein (CRP) >100 mg/L (adjusted OR, 2.71 [95% CI, 1.26-5.86]), and erythrocyte sedimentation rate (ESR) >40 mm/h (adjusted OR, 2.64 [95% CI, 1.07-6.51]). ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than in those without. DIC, clinically relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 2×
“Hospitalization ongoing 8 (2-18) 12 (3-33)”
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 3×
“Also collected were cases of presumed VTE unable to be confirmed radiographically (because of an inability to perform the necessary test secondary to diagnostic limitations imposed by this infection) but for whom all of the following criteria were satisfied: (1) clinical evidence consistent with VTE on vital signs, ph…”
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
Incidence of thrombotic complications in critically ill ICU patients with COVID-19
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.013 · Cited by 5,028
Hematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.031 · Cited by 2,885
Taylor, F., Toh, C.-H., Hoots, K., Wada, H., & Levi, M. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616068 · Cited by 2,285
Clinical Characteristics of Covid-19 in New York City
Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., Satlin, M. J., Campion, T. R., Nahid, M., Ringel, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2010419 · Cited by 2,234
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
Cui, S., Chen, S., Li, X., Liu, S., & Wang, F. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14830 · Cited by 1,806
Fox, S. E., Akmatbekov, A., Harbert, J. L., Li, G., Quincy Brown, J., & Vander Heide, R. S. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30243-5 · Cited by 1,526
Platelet Transfusion: A Clinical Practice Guideline From the AABB
Kaufman, R. M., Djulbegovic, B., Gernsheimer, T., Kleinman, S., Tinmouth, A. T., Capocelli, K. E., Cipolle, M. D., Cohn, C. S., Fung, M. K., Grossman, B. J., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1589 · Cited by 993
TOH, C. H., & HOOTS, W. K. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02313.x · Cited by 381
Cattaneo, M., Bertinato, E. M., Birocchi, S., Brizio, C., Malavolta, D., Manzoni, M., Muscarella, G., & Orlandi, M. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1712097 · Cited by 304
D-dimer Correlates With Proinflammatory Cytokine Levels and Outcomes in Critically Ill Patients
Shorr, A. F., Thomas, S. J., Alkins, S. A., Fitzpatrick, T. M., & Ling, G. S. (2002) · Chest · doi:10.1378/chest.121.4.1262 · Cited by 193
Lauzier, F., Arnold, D. M., Rabbat, C., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-013-3044-3 · Cited by 116
Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic
Obi, A. T., Barnes, G. D., Wakefield, T. W., Brown, S., Eliason, J. L., Arndt, E., & Henke, P. K. (2020) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2020.04.009 · Cited by 91
Zhang, C., Zhang, Z., Mi, J., Wang, X., Zou, Y., Chen, X., Nie, Z., Luo, X., & Gan, R. (2019) · Medicine · doi:10.1097/md.0000000000015833 · Cited by 86
Grimnes, G., Isaksen, T., Tichelaar, Y. I. G. V., Brox, J. H., Brækkan, S. K., & Hansen, J. (2018) · Haematologica · doi:10.3324/haematol.2017.186957 · Cited by 75
Cited by
Risk factors for severe and critically ill COVID‐19 patients: A review
Gao, Y., Ding, M., Dong, X., Zhang, J., Kursat Azkur, A., Azkur, D., Gan, H., Sun, Y., Fu, W., Li, W., et al. (2021) · Allergy · doi:10.1111/all.14657 · Cited by 1,402
Lamers, M. M., & Haagmans, B. L. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00713-0 · Cited by 983
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 941
Malas, M. B., Naazie, I. N., Elsayed, N., Mathlouthi, A., Marmor, R., & Clary, B. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100639 · Cited by 685
INSPIRATION Investigators, Mazloomzadeh, S., Khaleghparast, S., Ghadrdoost, B., Mousavizadeh, M., Baay, M. R., Noohi, F., Sharifnia, H., Ahmadi, A., Tavan, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.4152 · Cited by 625
Metadata
- Authors
- Al-Samkari, H., Karp Leaf, R. S., Dzik, W. H., Carlson, J. C. T., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., Leaf, D. E., Kuter, D. J., & Rosovsky, R. P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-07-23
- Volume
- 136
- Issue
- 4
- Pages
- 489-500
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3028989873
- Cited by
- 1,351
- References
- 20
- FWCI
- 35.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.